Skip to main content
. Author manuscript; available in PMC: 2019 Oct 7.
Published in final edited form as: Nat Rev Cancer. 2010 Aug;10(8):537–549. doi: 10.1038/nrc2887

Table 1 |.

HSP90 inhibitors in clinical trials

Structure Inhibitor Phase Route Source
graphic file with name nihms-1049638-t0004.jpg Tanespimycin (17-AAG) II/III Intravenous BMS
graphic file with name nihms-1049638-t0005.jpg Retaspimycin hydrochloride (IPI-504) II Intravenous Infinity
graphic file with name nihms-1049638-t0006.jpg BIIB021 CNF2024 II Oral Biogen Idec
graphic file with name nihms-1049638-t0007.jpg AUY922 I/II Intravenous Novartis
Resorcinol derivative* STA-9090 I/II Intravenous Synta
graphic file with name nihms-1049638-t0008.jpg IPI-493 I Oral Infinity
graphic file with name nihms-1049638-t0009.jpg SNX-5422 mesylate I Oral Pfizer, Inc.
Small molecule* BIIB028 I Intravenous Biogen Idec
Small molecule* KW-2478 I Intravenous Kyowa Hakko Kirin
Small molecule* AT13387 I Oral or intravenous Astex Therapeutics
Small molecule* XL888 I Oral Exelixis
Small molecule* HSP990 I Oral Novartis
Small molecule* MPC-3100 I Oral Myriad Pharmaceuticals
Nanoparticle albumin-bound 17-AAG ABI-010 I Intravenous Abraxis Bioscience

HSP90, heat shock protein 90.

*

The structures are not reported.